Revolutionary Therapeutics
First-in-class CEACAM-based biologics transforming the treatment of inflammation and joint disease.
About
CEACAM
Therapeutics
At CEACAM Therapeutics, we are pioneering a new class of regenerative biotherapeutics. Leveraging the CEACAM family of proteins, we are developing novel injectable treatments for osteoarthritis and other degenerative diseases that target inflammation at the cellular level. Our technology, licensed from University College Cork, is backed by global scientific expertise and a growing clinical program.
Products
Breakthrough Biologics for Lasting Relief
CCAM-111
Our human therapeutic –
a PSG1-Fc fusion protein that reduces inflammation and promotes tissue regeneration administered by injection
CCAM-241
Our equine therapeutic –
designed to restore mobility in horses by treating osteoarthritis. Fusion of equine CEACAM49 and IgG, administered by intra-articular injection.
The Osteoarthritis Burden
Joint degeneration is the leading cause of lameness in horses, and afflicts over 600 million people globally. Existing treatments target symptoms, not causes – often failing to halt disease progression. Our CEACAM-based approach offers a new path: disease modification through inflammation resolution and tissue regeneration.
The Future
Pipeline Programs
CEACAM is advancing a portfolio of disease-modifying therapeutics across both human and veterinary medicine.
CT-1111: Human OA (CCAM-111)
CT-2141: Equine OA (CCAM-241)
CT-1311: Traumatic Brain Injury (CCAM-111)
CT-1411: Wound Healing (CCAM-111)
Highlights
Revolutionary long-term benefits
Novel CEACAM-based therapeutic class
Dual-action mechanism: anti-inflammatory and regenerative
Clinically validated efficacy in OA models
Strong IP and scalability profile
No toxicity observed in early studies
Equine and human programs provide dual-path commercial opportunity
Our Partners
Collaborating for innovation
UCC is a comprehensive research-based globally oriented university where you can learn, study and prepare for the world and workplace in Ireland
Fusion Antibodies offer a complete end-to-end service from antigen design to cell line development. R&D Antibody Discovery Partner.
Launched in 2018, Kick Collective was established by Vicky Leonard who is on a mission to lift the standard of thoroughbred horse racing marketing.
Transocean is a Boutique Corporate Advisory and Asset Development Company Providing innovative capital and strategic solutions to our clients.